Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H27N.ClH |
Molecular Weight | 329.907 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=USUUKNCFNKZGEY-UHFFFAOYSA-N
InChI=1S/C21H27N.ClH/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19;/h4-13H,14-17H2,1-3H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C21H27N |
Molecular Weight | 293.4458 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-B enzyme and stimulating aromatic L-amino acid decarboxylase. Also the drug inhibits the dopamine re-uptake and has weak affinity to NMDA and muscarinic receptors. Budipine passes the blood-brain barrier, is metabolized by hydroxylation, and is excreted by both in urine and feces within 24 h.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27338 Gene ID: 4129.0 Gene Symbol: MAOB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904 |
5.0 µM [IC50] | ||
Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904 |
11.0 µM [IC50] | ||
Target ID: P20711 Gene ID: 1644.0 Gene Symbol: DDC Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PARKINSAN Approved UseFor combination therapy of Parkinson's disease. Launch Date1996 |
PubMed
Title | Date | PubMed |
---|---|---|
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines]. | 1984 |
|
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. | 2001 Aug |
|
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration. | 2001 Jun |
|
A new strategy for antidepressant prescription. | 2010 |
Patents
Sample Use Guides
The dosage is determined individually. The treatment should start with 3 times daily 10 mg budipine hydrochloride. If necessary, the daily dose should be increased at the earliest after 1 week to 3 x 20 mg budipine hydrochloride or 2 x 30 mg budipine hydrochloride.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://orbilu.uni.lu/handle/10993/17136
10(-7), 10(-8), 10(-9) mol/l of budipine significantly reduced release of TNF-alpha and Il-6 in PBMC and decreased apoptotic cell death after 50 hours and 74 hours in the SH-SY 5Y cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:58:45 GMT 2023
by
admin
on
Fri Dec 15 15:58:45 GMT 2023
|
Record UNII |
NBF4Q9307Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2747
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
3030419
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | |||
|
NBF4Q9307Q
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | |||
|
DTXSID60979889
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | |||
|
SUB35026
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | |||
|
236892
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000128225
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | |||
|
63661-61-0
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY | |||
|
264-388-5
Created by
admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |